Optimal glucocorticoid dose and the effects on mortality, length of stay, and readmission rates in patients diagnosed with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). J Investig Med 2019 Dec;67(8):1161-1164
Date
09/27/2019Pubmed ID
31554676DOI
10.1136/jim-2019-001105Scopus ID
2-s2.0-85075726557 (requires institutional sign-in at Scopus site) 4 CitationsAbstract
The burden of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is staggering on a national and global level. Yet, surprisingly, there is a profound lack of treatment standardization with glucocorticoids in the treatment of AECOPD. In this review, we bring attention to specific literature that use a cut-off of 60 mg prednisone equivalent per day when distinguishing between high-dose and low-dose glucocorticoid treatment. We hope this review encourages future research to begin incrementally lowering the cut-off dose of 60 mg to discover if mortality, length of hospital stays, and readmission rates change between high-dose and low-dose glucocorticoid treatment. The final hope would be to establish an optimal glucocorticoid dose to treat AECOPD and eliminate treatment ambiguity.
Author List
Kichloo A, Aljadah M, Vipparla N, Wani FAuthor
Michael M. Aljadah MD Instructor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Disease ProgressionDose-Response Relationship, Drug
Glucocorticoids
Humans
Length of Stay
Patient Readmission
Placebos
Pulmonary Disease, Chronic Obstructive
